People

Lee Anderson is a seasoned executive with over 30 years of experience in the biotechnology and diagnostic markets, including start-up companies with a focus on new product launches. Lee joined Genomic Health in 2004 as one of the initial commercial hires and held numerous leadership roles throughout his tenure, including Vice President of Sales and Global Customer Service. Upon Exact Sciences acquisition of Genomic Health in 2019, Lee served as the General Manager of the Precision Oncology business unit. Most recently Lee was the Chief Commercial Officer of Biofidelity Inc. Lee has successfully built and led high-performing commercial teams that have consistently exceeded their goals. His commercial experience includes leading sales, customer service, strategic accounts, commercial learning, and marketing teams. In addition, he has experience with acquisitions and divestitures, setting corporate strategy and vision, portfolio management and creating and ensuring cross-functional team environments. Lee also founded a life sciences consulting company, providing commercial strategy for start-up companies looking to secure capital investment. In addition to his corporate roles, Lee served as an advisory board member for the Department of Biological Sciences at Florida State College where he was instrumental in creating the Bio-Medical Science degree that is now offered at the institution. Lee holds a Bachelor of Science in Biology with a minor in Chemistry from Florida State University, magna cum laude.

Zhenya Lindgardt is the President and CEO and a Board Director of Sera, Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients. Prior to joining Sera first as a Board Director in 2021, Zhenya was a member of Executive Leadership team and a C-level executive at Uber Technologies, Inc. in charge of creating new long-term growth businesses on Uber platform, customer engagement and cross-sell across core businesses. In her role at Uber, Zhenya focused on incubating new and scaling current Uber’s two-sided marketplaces and services, driving experimentally proven incremental growth through customer retention and engagement (including cross sell, personalization, portfolio of loyalty programs, subscriptions) across all customer groups. Before Uber, Zhenya spent 19 years with the Boston Consulting Group (BCG) where she held several operating leadership roles as a Senior Partner and Managing Director of the firm. She was a leadership team member of the largest region (North America, >$5B in revenue) and practice area (Corporate Finance & Strategy, largest for BCG). In healthcare, one of Zhenya’s core areas of focus at BCG, she has worked across the full healthcare industry spectrum from R&D based biopharma and biotech, biomaterials to integrated healthcare systems, pharmacy benefit managers, payers and providers. Breadth of her knowledge of operations of each of these businesses spans from all aspects of operations, as well as corporate, therapeutic area/service line and portfolio strategy and M&A. Therapeutic areas she has expertise in include gene therapy, rare diseases, HIV, oncology, women’s and men’s health, vaccines, ophthalmology, endocrinology and cardiovascular among others. Zhenya also serves as the CEO of The Commons Project Foundation since 2021, focusing on modernizing industries enabling with their data, starting with health. One of TCP’s flagship products, CommonHealth, is a platform for individuals to access and share all their health data, including wearables, to share with their physicians and family. Broader ongoing monitoring and deploying insights from latest innovations will help clinicians to deliver better quality care and lower overall healthcare costs. Zhenya received an MBA from Harvard Business School and a bachelor’s degree, cum laude, from the University of Southern California. She lives in San Francisco with her husband and three daughters.

Wilson Er is identified as Vulpes Chief Investment Officer in the March 30, 2026 SEC Form ADV, with appointment month August 2025. This regulator-supported leadership appointment is absent from the public website roster. His biography and portrait require further independent primary material; no broader career details are inferred.

Eleanor Coffey advises Vulpes Life Sciences with expertise in molecular neurobiology, synaptic plasticity, protein trafficking and stress signaling. The own biography describes research leadership at Turku Bioscience Centre and work on brain protein kinases relevant to neurodegenerative and neuropsychiatric disorders. Clinical approval or therapeutic validation is not inferred from this research.

Martin Shenfield is named in the Vulpes senior advisor and non-executive director directory without a precise published governance capacity. His experience spans global asset allocation and institutional, mutual, UCITS and hedge-fund mandates, including Morgan Grenfell, Fidelity and TT International. His regional experience includes Asia-Pacific and emerging markets, and he advises family offices and EIS funds.

Will Garner is named in the Vulpes senior advisor and non-executive director directory, without a precise published capacity. His background includes financial research, investing and immigration law. He studied finance at Georgia, law at Nevada Las Vegas and business administration at Florida and completed Stanford executive education. Outside corporate titles in the biography require separate current verification.

Geoffrey Flynn is named in the Vulpes senior advisor and non-executive director directory without a precise published appointment title. His career included securities and money brokerage, international Reuters leadership and CEO of Instinet Asia Pacific. He retired from that operating career in 2002 and established property-restoration businesses in Italy.

Grant Williams is named in the Vulpes senior advisor and non-executive director directory; the precise capacity is not published. His biography describes trading experience across Asian equities and derivatives, including Robert Fleming, UBS, Credit Suisse and Jefferies in London, Tokyo, New York, Hong Kong, Sydney and Singapore. Historical trading roles are not treated as current employment.

Glenn Blasius is named in the Vulpes senior advisor and non-executive director directory, which does not identify his precise governance capacity. His career covers fixed-income credit portfolio management, trading and risk, including Antarctica Capital, Christofferson Robb and Company, Bear Stearns and other investment banks. He studied Engineering Physics at Cornell.

John A. Dawson, CBE, consults for Vulpes Life Sciences. He formerly led Oxford Biomedica for thirteen years, overseeing growth of its viral-vector cell and gene-therapy business and vaccine manufacturing work. His earlier roles include Cephalon and Serono. He is a Chartered Accountant and studied mathematics at Swansea. Outside board positions mentioned in the manager biography are not independently promoted to current appointments.

Teodoro Guarini manages the tail-hedge book and works on the AI-driven long-short equity sleeve of the Vulpes VaiL/S Tail Risk strategy. He joined in 2026 after more than five years with Eurex at Deutsche Borse, including derivatives clearing in Frankfurt and Asian-hours control in Singapore. His degrees are from Naples Federico II and Naples Parthenope, with an exchange term in Frankfurt.

Anthony Diggle joined Vulpes in 2013 with responsibility for agriculture and German property. Earlier consulting included investment diligence in agriculture, residential property and natural resources. His current role focuses on tangible assets and oversight of agricultural operations. He studied American and European Studies at Derby and Information Studies at Brighton.

Tam Seen Yee manages financial and management reporting at Vulpes. Previously she worked in auditing at a Big Four firm. She studied accountancy at Nanyang Technological University.

Jamie Diggle is a financial analyst at Vulpes focused on biotechnology and demographic investment research. He earned a Business Science degree specializing in finance at the University of Cape Town. His own biography describes completion of CFA Level 2, not a fully earned CFA charter.

Ana Gomes leads communications and investor relations at Vulpes, including research, public relations, branding and content. Her underlying biography also uses Corporate Communications Manager. Previously she worked in market research at Sands China in Macau. She studied Chinese and Economics at Edinburgh and Development Studies at Cambridge and speaks English, Portuguese, Mandarin and Cantonese.

Kim Ivey advises Vulpes with experience in private banking, asset consulting, risk oversight and quantitative portfolio management. Earlier employers include Merrill Lynch, Citibank, Towers Perrin and Commonwealth Bank. He founded Vertex Capital Management in 1998 and has held industry and charitable governance positions. Previous employer asset totals and charitable receipts are not Vulpes capital raised.

Philipp von Bernstorff manages special situations and turnaround investments at Vulpes and serves on the Testudo Fund investment committee. The own directory spells his surname Bernstoff while its biography uses Bernstorff; both refer to this same profile. He joined in 2012 after managing the Russian Opportunities Fund at Artradis and working in Moscow equity sales, trading and proprietary trading. He studied at MGIMO and Staffordshire University.

Alistair Nicholson manages agriculture investments and is Executive Chairman of Vulpes Agricultural Land Investment Company. He has invested in New Zealand farming since 2004. Previous positions include Alcor Investment Management CEO, Jardine Fleming New Zealand country leadership and equity trading and derivatives at Lehman Brothers in Hong Kong. He studied economics at Massey University.

Nicholas Robert Thibeault directs business development across the Vulpes platform and is a director in the March 2026 SEC filing. Earlier work includes investment management and banking at Canaccord Genuity, corporate advisory in Myanmar and fintech country leadership. He joined Vulpes in Singapore in 2019 and studied Economics and Politics at the University of Bath.

David Mackey is a Vulpes portfolio manager and CEO of Stronghold Capital. His career covers real-estate investment banking, REIT management and funds. Previous positions include corporate and strategy leadership at LMIRT, regional real-estate leadership at RBS, corporate finance at HSBC and institutional property research. He studied economics at the University of Tasmania.

Stuart Merrilees is COO of the independent UK operating company under the Vulpes brand. His work emphasizes operational efficiency and regulatory compliance. His background spans institutional investment management, capital markets and engagement with growing technology companies. He graduated from Newcastle University.

Sadiq Currimbhoy advises Vulpes on sustainability, developing investment ideas and assessing how businesses adapt to a low-carbon economy. Earlier roles include research and sustainability leadership at Maybank Kim Eng, investment strategy at Merrill Lynch and global strategy at NewSmith. He studied economics at the London School of Economics and University of Pennsylvania and sustainable business at Cambridge.

Bert Verdicchio is Vulpes Treasurer. His experience covers risk management, capital commitments and financial engineering across fixed income, credit, equities, currencies and derivatives. He has managed liquidity and working capital for Vulpes and its family-office sponsor, including borrowing arrangements, disposals and recoveries. He graduated from Yale.

Kirti Rani leads technology at Vulpes. Since joining in 2011 she has managed IT infrastructure and vendor-supported user services. Her earlier work was in software development. She holds a Masters in Computer Applications from Banasthali Vidyapith in India.

Chee Seng Ng joined Vulpes in 2019 after fund-accounting work at Citco and a controller position at Alphadyne, now Astignes Capital Asia. He studied Banking and Finance at the University of London. The current own directory calls him Chief Operations Officer; both MAS and the March 30, 2026 SEC filing identify him as Singapore Chief Executive Officer, and SEC also identifies Chief Compliance Officer. These jurisdiction-specific regulatory titles are distinguished from the UK CEO.

Jasmine Zhang is listed in the current Vulpes directory as Operations Consultant. Her underlying biography describes an earlier or inconsistent Chief Financial Officer title, joining in 2013 and overseeing financial affairs from 2019; this is retained as a source discrepancy rather than a second unqualified current appointment. Her background includes fund administration and asset-management finance. She studied accountancy at Nanyang Technological University.

William Overlock Crispin is Vulpes chief legal officer and a director identified in its March 2026 SEC filing. His legal work covers investment funds, private equity, corporate transactions and joint ventures across Asia-Pacific, the US, UK and Cayman Islands. He studied at Washington and Jefferson College, Pittsburgh School of Law, Boston University School of Law and Warwick Business School.

Stephen Charles Diggle founded Vulpes after the closure of Artradis Fund Management. He manages life-sciences investments and became CEO of the independently operated UK company in September 2024. His career began in finance in 1986 and includes investment-banking work in London, Sydney and Hong Kong. He studied Philosophy, Politics and Economics at Oxford. Artradis historical assets and profits are not Vulpes fundraising.

Chao Wu is vice president and head of ABB Group Ventures. ABB’s current native venture-directory model lists him in the group-level leadership section, distinct from the business-area Electrification and Motion teams. This profile represents that corporate venture executive and authentic ABB portrait, without assuming a same-name academic or technology professional.

Rayann Barazi is a ventures analyst at ABB Motion Ventures. He is part of the venture team supporting ABB’s Motion business and its industrial performance, energy efficiency and digital technology investments. ABB’s own directory identifies his exact role and authentic portrait.

Olga Peters heads ABB Motion Ventures, the venture and open innovation arm of ABB’s Motion business. Its mandate covers next-generation electric machines, power electronics and semiconductors, industrial AI, electrification and circular technologies. Her current title and authentic named portrait are published by ABB.

Analia Troncoso is ABB Motion’s global head of strategy, business development and sustainability. ABB includes her in its Motion Ventures directory as a business-area leader supporting the corporate venture and open innovation framework. The role concerns ABB’s drives, motors, powertrains and industrial performance business; no independent fund-management or personal-investor role is inferred.

Lukas Odelberg is an investment analyst at ABB Electrification Ventures, according to the latest live native ABB team directory and model downloaded in October2026. The business-area venture team focuses on electrification and industrial energy technologies. Earlier cached directory text naming a different analyst is not treated as his biography or evidence of that person’s current tenure.

Fatima Ben Larbi is an open innovation specialist in ABB Electrification Ventures. She works in the business-area venture and startup collaboration team, supporting links between emerging technology companies and ABB’s industrial expertise. ABB’s current named directory provides her role and authentic portrait.

Alexander Kolloge is an investment manager at ABB Electrification Ventures, supporting the business-area venture investment and startup collaboration program. Its published mandate includes next-generation power infrastructure, industrial energy systems and AI-driven energy optimization. His role and authentic portrait are confirmed by ABB’s own directory.

Cal Stock is an investment principal at ABB Electrification Ventures. He works within ABB’s corporate venture platform focused on scalable electrification, energy and industrial technology companies. ABB’s official directory identifies his exact role and named portrait; the same-name Vectr Solutions professional is not assumed.

Mads Møller is vice president and head of ABB Electrification Ventures. He leads venture investment and industrial collaboration within ABB’s electrification business, which backs technologies in grid modernization, DC power systems, AI-driven energy optimization and intelligent buildings. His current role and portrait are published in ABB’s official venture directory.

Ziv Reichert is published by Phoenix Court as Managing Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Tom Lambert is published by Phoenix Court as Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Sam Warren is published by Phoenix Court as Partner, Value Creation, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Robin Klein co-founded Phoenix Court and is a current board member, included in the investment function. The manager’s own2021 narrative distinguishes his mentoring and support for existing Latitude companies from leading new investments. This profile records current shared-platform governance and investment experience, without inventing an executive appointment or personal check.

Chris Kim (published Korean name 김동준) is a principal at Atinum Investment. He joined in 2025 after working as a gaming and entertainment analyst at CLSA Korea.

Remus Brett is published by Phoenix Court as General Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Rashad Mohammed is published by Phoenix Court as Director, Legal, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Rajeelan Thayalaseelan is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Paul Bishop is published by Phoenix Court as Managing Partner, Finance and Investor Relations, in its business operations, investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nuno Campos is published by Phoenix Court as Partner, Technology, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nin Pandit is published by Phoenix Court as Managing Partner, Value Creation, Special Projects, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nick Malkewitz is published by Phoenix Court as Associate, Spaces, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Mbali Mbatha is published by Phoenix Court as Partner, People, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Max Pavier is published by Phoenix Court as Partner, Talent, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Matt Peplow is published by Phoenix Court as Partner, Legal, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Laura Pospiech is published by Phoenix Court as Director, Spaces, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Kira Jang is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Judith Stephenson is published by Phoenix Court as Executive Assistant, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Jacob Hinton is published by Phoenix Court as Associate, Value Creation, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Emilie Spire is published by Phoenix Court as Partner, Special Projects, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Diana Barran is published by Phoenix Court as Non-Executive Director, in its board function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Darren Shapland is published by Phoenix Court as Non-Executive Director, in its board function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Dave Kashen is the published founder and partner of Fearless Ventures and an executive coach. He founded Worklife, acquired by Cisco, and Wellsphere, acquired by HealthCentral; his manager biography describes prior investing at SPO Partners and investment banking at Goldman Sachs. He earned an MBA at Stanford and a BS in economics at Wharton. His own current coaching website documents continued work with startup founders; clients are not inferred to be Fearless portfolio investments. December2025 SEC venture-SPV filings confirm his legal management alongside Seth Miller.

Ben Adler is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Amy Grimshaw is published by Phoenix Court as Partner, Marketing, PR and Communications, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Ambi Mistry is published by Phoenix Court as Partner, Portfolio Experience, in its business operations, investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Allan Nixon is published by Phoenix Court as Chief of Staff, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Noa Khamallah founded Don’t Quit Ventures after operating and building micromobility businesses. Allocator One identifies him as Lime’s first hire in Europe and a co-founder of GetCharged, later acquired. He runs DQV as its sole general partner.

Ian Ziddah has more than 20 years in telecoms and technology commercialisation. His experience includes product development at MTN Ghana, co-founding payments company M-Pay and evaluating and monitoring early-stage venture investments.

Shadi Chauke is a chartered accountant and media executive with more than 15 years in financial services. A former Deloitte South Africa partner, she owns and produces through Viva Pictures and Pop Up Media.

Chris Lister James is a technology startup investor with experience completing venture capital transactions and successful exits.

Ayanda Ngcebetsha brings experience in data analytics, artificial intelligence, cloud computing and telecoms infrastructure. Mamor identifies him as a chief data officer at Microsoft.

Liesl Mckay founded Tribel Consulting and previously led Rand Merchant Bank’s Foundery technology initiative. She advises startups on strategy and growth and mentors women founders.

Lindani Kgosietsile holds a master’s degree in financial economics from the University of Leicester. She previously worked at Stanbic Bank, Grant Thornton Botswana and Marlow Capital, supporting portfolio growth, operations and exits.

Moses Mufunguri has more than 15 years of experience in finance, consulting, telecoms, technology and fund management across East and Southern Africa, including work at Danoffice IT, Comtel Integrators Africa and Awethu Project.

Fuzlin Levy-Hassen is a chartered accountant with more than 25 years in venture capital, private equity and development finance. Her experience includes fundraising, origination, diligence and portfolio support, with previous investment leadership at IDC and the National Empowerment Fund.

Mamokete Ramathe founded Mamor Capital after more than 20 years in investment banking, corporate finance, private equity, infrastructure and M&A. She previously led mergers and acquisitions at Vodacom Group and co-founded infrastructure business Vulatel.

Seth Miller is the published founder and partner of Fearless Ventures. His own manager biography describes more than a decade at DBL Investors, most recently as general partner and investment-committee member, and earlier environmental-policy work for the White House and US Senate. He studied at the University of Pennsylvania and earned law/MBA degrees at Northwestern. The DBL225million across two historical funds belongs to DBL, not Fearless. Fearless’s undated biography also names a Maiyet chair role, which is not asserted independently current. December2025 SEC venture-SPV filings confirm current legal management alongside Dave Kashen.

Professor Julia Sutcliffe is an external Innovate UK Council member. Her UKRI biography identifies her as Chief Scientific Adviser at the Department for Business and Trade, not an Innovate UK employee with that title. Her background includes BAE Systems engineering and technology leadership.

John Patterson is an external Innovate UK Council member. His UKRI biography describes chairing software company 2iC, advising technology businesses and UK Innovation and Science Seed Fund, and earlier British Army and defence technology leadership.

Tunde Olanrewaju is an external Innovate UK Council member. His UKRI biography describes his McKinsey background advising organisations on digital transformation, analytics, strategy and operations. Outside employer titles in the older individual biography are source-attributed.

Annalisa Gigante is an external Innovate UK Council member. Her UKRI biography describes advisory and board work spanning advanced materials, enterprise investment, deep technology and AI, alongside a career leading innovation across international businesses. Cambridge Enterprise affiliation: Annalisa Gigante is listed by Cambridge Enterprise as External Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

John Gibson is an external Innovate UK Council member. His May 2026 UKRI biography describes his commercial leadership at AI company Faculty and earlier government, Nesta and Fingleton Associates work on innovation, automation and open banking.

Chris Ganje is an external Innovate UK Council member. His published UKRI biography describes co-founding and leading AMPLYFI, which uses machine learning for business intelligence, and earlier technology, strategy and operations work at BP. The biography’s outside employer titles are attributed to that source.

Scientist, entrepreneur and investor Harry Destecroix is an external Innovate UK Council member. His UKRI biography describes founding Science Creates and SCVC, leading smart-insulin company Ziylo to its 2018 acquisition, and co-founding glucose-sensor company Carbometrics.

Guy Woolley is listed by Innovate UK as Chief Operating Officer on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Dave Wilkes is listed by Innovate UK as Director Innovation Infrastructure on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Boryana Stambalova is listed by Innovate UK as Director Finance on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Claire Spooner is listed by Innovate UK as Director Innovation Service on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Rob Saunders is listed by Innovate UK as Director Clean Energy on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Scott O’Brien is listed by Innovate UK as Director of Innovation Finance on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Fran McIntyre is listed by Innovate UK as Managing Director, IUK Business Connect on its official July 2026 Executive Leadership Board directory. Her role leads the Business Connect delivery unit; this is distinguished from private fund management.

Sarah Goulding is listed by Innovate UK as Director Life Sciences on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Gary Cutts is listed by Innovate UK as Director Digital and Technologies on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Dean Cook is listed by Innovate UK as Director Business Growth & Global on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Sarah Bell is listed by Innovate UK as Director Business Engagement Strategy on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Bruce Adderley is listed by Innovate UK as Director Advanced Manufacturing on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Kath Mackay is listed by Innovate UK as Interim Managing Director on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Entrepreneur and board director Tom Adeyoola is Innovate UK’s Executive Chair. His agency biography describes his Cambridge education, founding Metail, supporting Elvie and Verco, and co-founding Extend Ventures. These career affiliations are biography context, not additional institutional financing checks.

Annie Santos was explicitly identified as Head of Ventures Operations in Murali Venkatesan’s first-hand2024 account of the Danaher educational visit, reproduced in Charlie Purtell’s own public post. This is a dated operational affiliation rather than confirmation of continued employment inOctober2026; exact tenure dates, biography and authentic individual portrait remain undisclosed in the reviewed source. Unrelated same-name automotive and community professionals are not merged.

Blue Venture Fund associate and published Ultromics board observer. Previously worked in finance and commercial strategy at Becton Dickinson and interned at JJDC and Joyance Partners. Holds a Chicago Booth MBA and a Brigham Young accounting degree. The observer role does not imply a personal investment or a board director seat.

Mayo Clinic cardiovascular medicine leader and clinical research collaborator whose echocardiography expertise contributed to development and validation of EchoGo. Ultromics’ own About page describes her collaboration; it does not identify her as an employee, director or formal advisory-board appointee.

Ultromics chief regulatory and compliance officer. Previously led regulatory compliance at Perspectum across multiple international markets. Holds an Oxford doctorate in safety-critical systems design.

Ultromics chief experience officer leading service operations and customer experience. Previously led operations at Oxford’s Cardiovascular Clinical Research Facility and delivery of the EVAREST echocardiography study. Holds chemistry degrees and a toxicology doctorate focused on metabolic biomarkers.

Ultromics chief commercial officer leading global commercialization. Previously held cardiovascular device roles at Guidant, Boston Scientific, Abbott and Cardiva. Holds biomedical science, psychology and cardiac physiology degrees from Ohio University.

Ultromics chief product officer, formerly its head of R&D. Previously developed diagnostic technologies at Perspectum, Oxford University Hospitals and GlaxoSmithKline. His experience includes diagnostics, intellectual property and technology transfer.

Ultromics COO leading strategy, operations and business development. Previously led Philips’ global cardiology informatics business and enterprise integration services. Holds an Imperial College chemical engineering MEng and an INSEAD advanced management certificate.

Academic founder and non-executive director, according to his own current Ultromics biography. Professor of Cardiovascular Medicine at Oxford; established its Cardiovascular Clinical Research Facility in 2009. His research generated intellectual property underpinning Ultromics. The separate leadership roster still calls him chief medical officer; that source discrepancy is retained in the evidence map.

Ultromics founder and CEO. His Oxford doctoral research with Paul Leeson produced the echocardiography AI technology behind the 2017 spinout. He has led EchoGo development and the company’s growth into clinical cardiovascular imaging.

Samuel Ngai represented Danaher Ventures as Asia head and Vice President of Science and Technology at the LINK-J event on19July2024. The2025 BIO Korea programme and organizer Benelux Chamber seminar explicitly call him former head of Danaher Ventures Asia. The2024 affiliation and authentic named event photograph are historical; a precise departure date and current Danaher employment are not asserted. He is distinct from same-name civic and social-service professionals.

Charlie Purtell is named Vice President of Danaher Ventures in the2026 BioInnovation Group Executive Summit organizer agenda. His own2026 public post discusses AI-driven drug discovery and Danaher’s investment partnership in Automata; a2023 first-hand Murali event post also identified him as the venture unit’s vice president. No personal investment ticket, exact employment start or unverified headcount is inferred.

Alex de Winter invests in life sciences tools and diagnostic startups for Danaher Ventures. His Berkeley Haas first-hand2022 profile calls the unit Danaher Equity Ventures and his PMWC2024 speaker biography identifies him as Vice President of New Ventures, following GE Ventures, Mohr Davidow, Pacific Biosciences and454LifeSciences. The published RESI conference judge roster retains the Danaher title. These dated public affiliations support the unit relationship, without an invented exact appointment day.

Jay Kalish has extensive legal, investor relations and management experience over the past 20 years.

Kirk Haney is the Co-Founder & Managing Partner at Radicle Growth.

Thanasis has been a venture investor for 19 years.

Over John’s 20+ year career as a venture investor, he has been a founder of Blacksmith Capital and True Ventures, both of which were defined by his passion for early-stage investing and growing companies.

John has been a venture investor for over 20 years.

Allen is a successful entrepreneur and experienced corporate executive in the healthcare and medical informatics space.

Dr.

Yori Nelken is a serial entrepreneur and angel investor with over 18 years of leadership experience driving startup companies from concept to success.

Eduardo Shoval has over 25 years of experience as a serial entrepreneur, angel investor and mentor in high-tech management, with a proven track record steering companies through the challenging stages of rapid growth.

Avi is General Partner at OurCrowd First, israel’s most active early-stage venture fund, seeding and scaling high-tech companies that are computing and actuating the connected world.

Jeremy is Israel’s only active venture capitalist and professional basketball player, a unique combination for leading a sports tech investment fund.

Christoph is an entrepreneur and venture capital expert with a passion for early-stage startups and sports.

David is responsible for New Business Relations and Account Management with Investors from LATAM.

Orly Wolynetz is the project manager for the OurCrowd funds team.

Before joining OurCrowd, Gilad worked as an investment manager at Psagot Mutual Funds, overseeing various mutual funds targeting different sectors and regions, managing a $80 million portfolio.

Ely Razin is a seasoned FinTech leader and investor, with extensive experience as both entrepreneur and as senior executive in the large corporate world.

Jeff Khoury is Vice President of Investor Relations at OurCrowd, leading the global Account Management team responsible for investor engagement and fundraising across venture capital and other alternative investments.

Amit Almog is an Account Manager at OurCrowd, with a background in financial planning, trading, and sales.

Sidhesh Kanade is an Account Manager at OurCrowd, with over six years of experience across investment banking, private credit, and alternative investments, specializing in financial analysis, deal execution, and portfolio management.

Rousselle Banza is an Account Manager at OurCrowd, bringing over six years of experience across private capital markets, with a strong foundation in private real estate and exempt market securities.

Originally from Argentina, Gustavo made Aliyah to Jerusalem in 2021.

Sean McMahon is a Senior Account Manager at OurCrowd who works mainly with investors in North America.

Zohaib Ahmad is a Senior Account Manager at OurCrowd who works with investors in Canada and the Northeast region of the United States.

Andrew brings extensive experience in investment management strategy, operations, and acquisitions to SoftBank.

Priyanka works as an Associate Director out of the Toronto office and is responsible for the Eastern region of the United States.

Originally from England, Eli made Aliyah in 2013.

Hilton serves as an advisor to Bangkok Bank PCL since 2002. He spent 14 years with Citibank Europe/Africa Div and Asia Pacific Div ; A/P Consumer Bank Division Treasurer. Prior to that he managed Visa Australasia through the ‘90s.

Daniel is an Account Manager at OurCrowd, working with clients across Europe and APAC.

Steve is a co-founder and serves as Co-Chairman of Pathstone, which serves families, family offices, and endowments and foundations.

Kiyoshi Habiro is the CEO of ORIX UK and Europe.

Daniel Ivanov started his career as an Investment Strategist at Pilgrim Asset Management, a hedge fund with over $200M AUM, before joining JSCapital, an investment bank that founded the Israeli Blockchain Association (where Daniel was a Board Member) and VentureIsrael (VC).

David serves as Partner of Investor Relations in Toronto, breaking new ground for OurCrowd and startup investing in Canada.

Alan is leading the development of OurCrowd's presence in Hong Kong from a licensing and regulatory perspective, as well as working on the maintenance and expansion of investor relations in Hong Kong and Asia.

Ben Plotkin is the Vice Chairman, Stifel Financial Corp.; Executive Vice President, Stifel, Nicolaus & Company, Inc.; and Executive Vice President, KBW.

Publicly named by BQPhy founder alongside IBM Ventures investment team; third-party Principal title is not used without primary confirmation.

Named by IBM colleague as IBM Ventures team member at current Boston Open Accelerator event; unrelated namesake public profiles are not reused.

Own 2026 announcement confirms transition from IBM M&A into venture investing and portfolio development.

Own 2026 posts document IBM Ventures portfolio development, hiring and events; external databases suggest Partner but that precise title lacks own public confirmation.

Own current profile describes helping IBM Ventures portfolio companies work with IBM across business and commercial partnerships.

Joined IBM Ventures after five years leading strategy and transactions at IBM Research; current participation corroborated by June 2026 first-person interview.

Publicly named as head of strategy for IBM Ventures in April 2026.

Publicly named at IBM-sponsored April 2026 corporate venture session.

Leads IBM venture investments, enterprise AI and quantum strategy, and startup commercialization.

Haruyo Konishi is a member of Shionogi’s CVC Group focused on evaluating technologies and science-based investment opportunities. She joined the company in2012 and previously conducted drug-discovery pharmacology research, including fibrosis and hearing-loss programs.

Kazuyuki Saito is a member of Shionogi’s CVC Group. He joined the company in2017 and brings global supply-chain strategy, commercial supply-chain development and startup-partnership experience.

Emi Kato is a member of Shionogi’s CVC Group and holds an MBA. She joined the company in2012 and previously worked in pharmaceutical sales and pain-management marketing, including regional sales strategy in Japan.

Kensuke Matsumura is a member of Shionogi’s CVC Group. He joined the company in2020, with neuroscience, AI-assisted drug-discovery and global clinical-development experience. His doctoral research at Osaka University addressed neurodevelopmental disorders, and his Shionogi research has included dementia and rare diseases.

Li Jiang is a member of Shionogi’s CVC Group in corporate planning and strategy. He joined the company in2013 and previously worked in pharmaceutical sales, Asian business development and joint-venture management. He is distinct from Makers Fund advisor Jiang Li and Sunflower founder Liu Jiang.

Keisuke Kusumoto leads Shionogi’s CVC Group as general manager within corporate planning and strategy. He joined Shionogi in2008 and previously worked in drug-discovery research and new-product planning, including anti-obesity drug development and asset evaluation. He holds an MBA.

Kenji Matsuo is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Vice President, Internal Control Department. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Masako Kudou is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Corporate Strategy Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Toshiyuki Asaki is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Drug Discovery Research Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Tetsuya Numa is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Vaccine Business Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Satoru Yoshimoto is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Integrated Disease Care Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yoshinori Yurugi is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Pharmaceutical Commercial Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Takeki Uehara is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yousuke Miharu is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, DX Promotion Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Masashi Deguchi is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Sustainability Management Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Tatsumori Yoshida is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Pharmaceutical Technology Research Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yasuyoshi Iso is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, President, Shionogi Pharma Co., Ltd.. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Takeshi Shiota is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Akira Kato is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Supply Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Kazuhiro Hatanaka is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Corporate Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Toshinobu Iwasaki is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yoriko Goto is an independent outside director and chairperson of Shionogi’s audit and supervisory committee. Her background includes professional-services and financial-sector leadership at Deloitte.

Fumi Takatsuki is an independent outside director and audit and supervisory committee member at Shionogi. She is a partner at Oh-Ebashi LPC & Partners, with international corporate-law and Chinese life-sciences/healthcare experience. She first became a Shionogi outside director in2020 and a committee-member director in2025.

Shuichi Okuhara is an independent outside director and audit and supervisory committee member at Shionogi. His background includes venture-capital management and evaluating innovation partnerships and corporate investment.

Koji Hanasaki is a Shionogi director and audit and supervisory committee member. His prior company roles include finance and accounting, corporate strategy, global business and supply leadership. He became a committee-member director in June2025.

Noriyuki Kishida is a Shionogi director and member of its audit and supervisory committee. He joined the company in1984 and held communications, human-resources, administration and corporate-supervisory leadership roles before becoming an auditor and then a committee-member director.

Keiichi Yoshii is an independent outside director of Shionogi, appointed in June2026. His corporate-management background includes leading Daiwa House Industry as president and later chairman and CEO, with overseas-business responsibility.

Kyoko Hirose is an independent outside director of Shionogi, appointed in June2025. She is president of Hirose Manufacturing, a global industrial-sewing-machine component business, and vice-chair of the Osaka Chamber of Commerce and Industry. Her board expertise includes organizational culture, diversity, globalization and risk management.

Takaoki Fujiwara is an independent outside director of Shionogi. He formerly led Hanshin Electric Railway as president and chairman and held leadership roles at Hankyu Hanshin Holdings and Hanshin Hotel Systems. He became a Shionogi outside auditor in2018 and an outside director in2023.

Hiroshi Ozaki is an independent outside director of Shionogi. He formerly served as president and chairman of Osaka Gas and brings energy-industry and corporate-management experience to the board. He joined Shionogi’s board in June2019.

Keiichi Ando is an independent outside director and chairperson of Shionogi’s board. His background includes executive leadership at Sumitomo Mitsui Banking Corporation and New Kansai International Airport Company. Shionogi first appointed him an outside director in June2016.

John Keller is a Shionogi director and senior executive officer overseeing the R&D Supervisory Unit. He joined Shionogi Inc. in 2010 and formerly led that US subsidiary as president and CEO, before holding global-business and corporate-strategy leadership roles. He became a parent-company director in June2025. This pharmaceutical executive is distinct from Redlist co-founder John Keller.

Isao Teshirogi is Shionogi’s representative director, president and CEO. He joined the company in 1982 and became president in 2008, leading its global research, development and corporate transformation strategy. His doctorate is publicly listed by the company.

Brant Shrimplin’s public regulatory disclosure identifies investor-relations work for venture fund Community Access Management III starting December17,2021. He separately co-founded 626 Financial in 2009 and is a Managing Director there, advising entrepreneurial families on wealth, private markets and real estate. He began his financial-services career on the New York Stock Exchange in 1999 and holds a business-administration degree from Western Washington University.

Tom Anderton is a published member of the Community Access Fund investment team and is identified as Thomas William Anderton, a member of Community Access Management III LLC, in its March2024 adviser filing. He is also Managing Director at the separate wealth-advisory firm 626 Financial. He studied finance at the University of Florida and earned an MBA at the University of Chicago; his investment career included Oppenheimer before returning to Kalamazoo. Community Access Fund does not publish a more specific operating title for him.

Sean Sternbach is Managing Partner of Community Access Fund, a role disclosed since September 2019 in his public regulatory record. He supports founders through Venture Out, which helps people from technology companies validate startup ideas. His earlier career includes product management at Amazon, co-founding Gingr and a Techstars contractor role. His Cloud Capital investment-adviser work is a separate disclosed activity.

Maven operations executive with experience in acquisitions, due diligence, legal and financial structuring, asset management and investment operations. Companies House identifies him as a current director of Maven Cognition.

Richard Male leads Maven Cognition’s strategy, fundraising, investor support and investment governance. His background combines venture investing, research commercialisation and public–private partnerships, with particular experience in applied AI, robotics, industrial technology and software.

George Van Horn is published in Parkwalk’s institutional team as Vice President, IP Capital. This IP Capital affiliation is distinguished from the core Parkwalk investment team.

Wisdom Yemi is published by Parkwalk as Investment Associate.

Samiksha Rai is published by Parkwalk as Investor Relations Assistant.

Olivia Smith is published by Parkwalk as Investor Relations Manager.

Moray Wright is published by Parkwalk as Chief Executive Officer.

Lucy Allen is published by Parkwalk as Marketing Manager.

Helen Redmond is published by Parkwalk as Chief Risk Officer.

Gordon Lawson is published by Parkwalk as Non-Executive Chairman.

Georgia Docker is published by Parkwalk as Senior Investor Relations Associate.

Danielle Acuy is published by Parkwalk as Senior Business & Data Analyst.

Chloe Woodacre is published by Parkwalk as Head of Investor Relations.

Professor David Onions is Norcliffe Capital’s Chief Scientific Officer and science specialist. The manager biography identifies a PhD in virology and previous roles as Professor of Veterinary Pathology at the University of Glasgow and director of the Leukaemia Research Fund’s Human Virus Centre. It describes scientific and commercial leadership, due diligence and mentorship of life-sciences founders. His scientific role is distinct from Patricia Reynolds’s CEO/director role and does not itself establish a personal company investment.

Patricia Reynolds is the founder and CEO of Norcliffe Capital. Its current biography describes over30years in finance, including15years at RBS, and work since2013 in pre-investment due diligence, EIS/SEIS equity fundraising and post-investment business management across life sciences, healthcare, technology and IoT. Companies House identifies Patricia Elaine Reynolds as the active director of Norcliffe Capital Limited, appointed1February2018. Exact career-date labels are company biography claims; no personal portfolio check is inferred.

Sungwook Moon (문성욱) was appointed head of SK Networks Americas in March2025 according to the parent’s official annual report. The appointment concerns the US investment subsidiary formerly named HICO Capital, not the separate HICO Ventures fund-manager roster. Current tenure and an authentic portrait have not been independently verified; no same-name person in government or another investment firm is assumed.

Changho Jin (진창호) was appointed head of HICO Capital, SK Networks’ US corporate investment subsidiary, on23 May2024 according to the parent’s official filing. The parent’s 2025 annual report states that he was replaced in March2025 after the vehicle was renamed SK Networks Americas. This profile identifies that source-qualified corporate executive and does not assume identities or portraits of same-name professionals.

Gina Moon is a Yale School of Management MBA student in the class of2027. Yale identifies her pre-MBA position as associate at HICO Ventures and her earlier work as manager of global investment at SK Networks. She studied business administration and Chinese at Hanyang University. Her HICO affiliation is historical; the firm’s older website listing does not establish current employment.

Hardik Mittal is a partner at HICO Ventures. Raised in New Delhi and educated in electrical engineering at UCLA, he previously worked in product marketing for timing products at Texas Instruments before joining SK Networks’ investment business. His published experience includes direct startup investing and fund investments across frontier technology.

Carlos Trenchs co-founded Aldea Ventures and is identified as its Partner by his current own Masia profile, where he also serves as Co-Founder and Chairman. CNMV lists Carlos Trenchs Sainz de la Maza as an Aldea statutory director. He previously built CaixaCapitalRisc and teaches venturecapital/corporateventuring atESADE. His personal/predecessorinvestmenthistory isnotallocated toAldea directchecks.

Oversees fund accounting, financial operations, and performance reporting across Aldea's platform. Adrià is responsible for Aldea's financial operations, fund accounting, and reporting infrastructure, ensuring accuracy, consistency, and transparency across the firm's funds and portfolios. He works closely with the investment and operations teams to support disciplined execution and institutional-grade reporting for Aldea's LP base. Prior to joining Aldea, Adrià worked in portfolio management and financial analysis roles at Maverick SMF (London), and previously held analytical positions at Investec and the University of Oxford. His background spans fund operations, performance analysis, and financial controls across institutional investment environments. Adrià holds a Master's degree in Finance from Bentley University.

Leads Aldea's data infrastructure, analytics, and portfolio intelligence. Alina oversees the design and development of Aldea's data and analytics platform, supporting investment decision-making, portfolio monitoring, and fund-level reporting across the firm. Her work sits at the intersection of venture capital, data engineering, and financial modeling, enabling a more systematic and insight-driven investment process. Her background combines academic research in venture capital with hands-on experience building data pipelines, analytical frameworks, and performance models for alternative investment strategies. At Aldea, she works closely with the investment team to translate qualitative conviction into structured analysis across managers, companies, and portfolios. In parallel with her work at Aldea, Alina teaches Venture Capital at ESADE and Business Analytics at the University of Barcelona, reflecting her strong grounding in both theory and applied practice.

Leads sourcing, diligence, and portfolio engagement across Aldea's investment platform. Gabrielle brings over a decade of experience sourcing and evaluating early-stage technology investments, with a particular focus on founder quality, market dynamics, and execution risk. She works closely with Aldea's partners across fund and direct strategies, supporting investment decisions from initial conviction through portfolio engagement. Prior to Aldea, Gabrielle held operating and investment-facing roles across Europe and the U.K. She previously served as COO at Learn Amp, where she supported the company's growth and product expansion, and earlier worked on international expansion initiatives at Mitiga Solutions, a deep-tech company operating across multiple geographies. At Aldea, Gabrielle is a core member of the investment team, partnering with managers and founders throughout the lifecycle and contributing to portfolio construction, diligence processes, and ongoing support. She holds a degree from the University of Cambridge and an Executive MBA from IESE Business School.

Leads operations, investor relations, and institutional execution across Aldea's platform. Daniela brings over 13 years of experience across investment banking and alternative investments, with deep expertise in investor relations, capital formation, and firm-wide operations. She is responsible for translating Aldea's strategy into disciplined execution across funds, LP relationships, and institutional processes. Prior to joining Aldea, Daniela held roles spanning M&A, capital markets, and investor relations across London and Milan. She previously led Investor Relations at a Barcelona-based alternative investment firm, working closely with institutional and family office investors across Europe. At Aldea, Daniela partners closely with the investment team to support fund launches, LP engagement, reporting, and governance, ensuring a high standard of transparency, rigor, and operational excellence as the platform scales. Daniela holds a BA in International Economics and Management and an MSc in Finance from Bocconi University, both cum laude.

Leads direct investments backing founders building frontier technologies, while serving across Aldea's investment committee and fund platform. Andrew focuses on technically complex, founder-led businesses scaling from early conviction to global impact. He brings a founder-first perspective shaped by operating, investing, and building across both the U.S. and Europe. Before Aldea, Andrew was a Partner at Alumni Ventures, where he made more than 50 investments and worked through a period of significant scale as the firm grew from approximately $500 million to $1.5 billion in assets under management. Earlier, he was an investor at Mithril Capital—founded by Peter Thiel—and at GCM Grosvenor, where he helped manage a $2 billion emerging manager mandate on behalf of the Teachers Retirement System of Texas. His investment experience spans category-defining technology businesses across compute, neurotechnology, robotics, and infrastructure. Having founded and operated companies himself, Andrew partners closely with founders at moments of technical and organizational inflection. He began his career as a CPA at Ernst & Young and holds an MBA from Columbia Business School.

Leads fund strategy, manager selection, and portfolio construction across Aldea's integrated investment platform. Alfonso brings over two decades of experience across venture capital and company building, with a focus on portfolio construction, manager evaluation, and long-term capital allocation. His work centers on identifying emerging managers early and building diversified portfolios designed to perform across cycles. Prior to co-founding Aldea, Alfonso was employee #1 at Nauta Capital, where he helped scale the firm from its first €8m fund to over €500m in assets under management. During this period, he participated in more than 65 investments across Europe and the U.S., gaining deep exposure to fund formation, portfolio dynamics, and cross-border venture ecosystems. Earlier in his career, Alfonso served as CFO/COO of a transatlantic technology scale-up, giving him an operator's perspective on growth, capital efficiency, and organizational scaling. He works closely across Aldea's investment activities, contributing both to fund strategy and direct investment decisions. Alfonso holds a BBA and an MBA from ESADE Business School.

Samuel Kim is managing partner of HICO Ventures and managing member of HICO Management LLC, as confirmed by its March2026 SEC filing. His career spans investment banking, cross-border corporate development and venture investing. He previously headed SK Networks’ US investment vehicle, then HICO Capital, and was replaced in that holding-company role on 23 May2024; that historical change does not end his separately documented manager affiliation.

Leads Aldea's long-term platform strategy and institutional partnerships, ensuring alignment across funds, managers, and investors. Gonzalo brings more than three decades of experience spanning law, investment banking, entrepreneurship, and long-term capital formation. He focuses on building durable investment platforms grounded in trust, governance, and multi-generational alignment. Before founding Aldea, Gonzalo held senior roles across legal, advisory, and financial institutions, including Cuatrecasas, Gómez-Acebo & Pombo, and GBS Finance. His career has been shaped by working closely with founders, families, and institutional investors navigating complex ownership structures and long-horizon decisions. In parallel with his investment work, Gonzalo has served on multiple boards, including Inversiones y Servicios Publicitarios, a family-owned holding company operating across 12 countries. These experiences inform Aldea's emphasis on disciplined governance, institutional rigor, and partnership built over time. Gonzalo holds a Law degree from the University of Barcelona and completed Columbia Business School's Advanced Management Program.

Giovanna Dossena is identified as founder on the Milan Add Value srl website. Its published biography describes her background in investment management and academic business research. The current AVM SGR team independently identifies her as principal of AVM SGR and AVM Associati, with a career in private equity and business advisory and a University of Bergamo professorship. These outside affiliations are source-attributed; no automatic AVM manager fund or personal check is attached to Add Value.

Mike Karim co-founded and previously led Oxford Endovascular. His older company biography describes international medical-device experience in leadership, sales, marketing, fundraising and bringing devices to market. His current personal consulting website and Synapto Ventures biography explicitly describe the Oxford Endovascular CEO role in the past tense. The transition date and successor are not verified; the older company directory is not treated as evidence of his current CEO status.

Zhong You is listed as Oxford Endovascular’s technology director. He is a professor of engineering science whose research includes origami structures and minimally invasive medical devices. His company biography describes Wellcome Trust Centre of Excellence support for prototype medical-device development.

James Byrne is listed as Oxford Endovascular’s clinical director. He is a professor of neuroradiology and consultant neuroradiologist with extensive experience treating brain aneurysms, training physicians and developing and testing device prototypes. The company describes his clinical background as contributing to its neurovascular device development.

Chas Taylor is listed as chairman by Oxford Endovascular. His published company biography describes an entrepreneurial medical-device career that includes founding and leading Veryan, Novate and MedNova, fundraising and exits. His work spans device development, regulatory planning and commercialization. He is distinct from Charles Taylor, the existing Ozlo Sleep co-founder.

Andreas Munk Holm is a Venture Partner at Isomer Capital working with emerging European venture managers. He co-founded The European VC, an industry podcast and network that also organises limited-partner syndicates. The advisory affiliation is distinct from automatically attributing personal company investments.

David Cruz e Silva is a Venture Partner at Isomer Capital supporting research into emerging European venture managers. He co-founded The European VC, which operates a venture-industry podcast, network and limited-partner syndicates. These separate activities do not establish personal checks into each Isomer portfolio company.

Philip Walker is a Venture Partner at Isomer Capital working on its Swiss and DACH presence. He previously was a Partner at Obviam and worked in emerging-market venture capital through Forestart and NXT-ALT.

Charles Schrager is a Venture Partner at Isomer Capital with experience as a limited partner, general partner, director and technology executive. He previously was a Partner at Penta Capital and a Managing Director in Credit Suisse’s financial-institutions investment-banking group.

Hiroshi Baba is a Tokyo-based Venture Partner at Isomer Capital supporting Japanese limited partners’ innovation programmes. He also advises the Japan Professional Football League. Previously he led NTT Docomo’s corporate venture-capital business and its international expansion.

Pascal Isbell is an Investment Adviser and investment-committee member at Isomer Capital. He has built an angel-investment portfolio, co-founded Lancea Partners in 2005 and previously worked in technology, media and telecommunications investment banking in the United States and Europe. Isomer’s card heading spells Pascall, while the biography, portrait filename and own professional-profile URL consistently use Pascal.

Marloes Dellemann is Office Manager at Isomer Capital, supporting business operations, events and the investor community. She has also written and published a Dutch children’s book.

Laura Corrigan is an Analyst at Isomer Capital supporting sourcing, diligence and investment execution across funds, co-investments and secondaries. She also coordinates ecosystem initiatives including the European VC Awards. Her earlier work involved early-stage technology businesses and a UK investor community.

Kevin D’Souza is an Associate at Isomer Capital working across fund investments, co-investments and secondaries. Previously he invested at Boldcap, evaluating AI seed opportunities across India and the United States, and worked on fund underwriting, direct investments and secondaries at TrueBridge Capital Partners.

Nicola Fleetwood is Head of Finance at Isomer Capital. She oversees accounting, corporate and fund reporting, cash management and Luxembourg operations. Her earlier career includes other finance positions in private equity. A separate 2025 legal Team LLP ownership disclosure is not treated as an independently closed investment fund.

Omolade Adebisi is a Principal at Isomer Capital focused on European venture-fund and company secondaries. Previously she helped establish a venture-capital secondaries fund in the Middle East, worked at Coller Capital and started her banking career at Citi. She also founded a marketplace startup. Her own professional profile uses Omolade Rachel Adebisi.

Michael Joyce is a Principal at Isomer Capital working across fund investments, secondaries and company co-investments, with data-analysis responsibilities. He previously served as an Investment Director at Cambridge Associates and researched emerging technologies at Fidelity Investments.

Thomas Schneider is a Partner and investment-committee member at Isomer Capital. He leads fundraising and investor relations and contributes to manager research in continental Europe, particularly France and Italy. Previously he led Russell Investments’ Southern Europe business. UK legal filings identify Thomas Archibald Oscar Schneider.

Chloe Dagnell is a Principal at Isomer Capital, responsible for its pipeline of new venture-fund managers and co-management of a separate vehicle for one limited partner. She also researches climate investment and ESG. Her earlier consulting work included supporting a World Bank accelerator and a UK government technology-for-good fund.

Leads corporate legal and governance functions, with extensive in-house legal experience across regulated industries.

Otolaryngologist directing clinical strategy while maintaining a cochlear-implant surgical practice; Cochlear describes a two-thirds-time commitment.

Appointed in 2026; experienced in organizational transformation, culture and capability development.

Leads product industrialization, procurement, manufacturing and logistics, with extensive operations experience.

Leads global information-technology strategy and systems, with prior digital-services experience at Ventia.

Medical-device and pharmaceutical executive responsible for product planning, commercialization, market access, brand and communications.

Medtech executive with international management and commercial experience, including more than twenty years at Johnson & Johnson.

Former services president and CFO, experienced in customer-focused technology businesses.

Audiologist and long-serving Cochlear commercial leader, responsible for North American strategy and operations.

Leads hearing-technology research, development, business development, quality and regulatory responsibilities.

Former BCG healthcare consulting leader and research scientist; appointed CFO in January 2025.

Physician and research leader experienced in clinical medicine, scientific innovation and healthcare commercialization.

Experienced chair and director across financial services, resources, health insurance and infrastructure.

Former banking executive and listed-company CFO, experienced in financial management, audit and enterprise risk.

Former media and digital-business chief executive, experienced in strategy, transformation and corporate governance.

Medical-device and pharmaceutical executive with international commercialization and leadership experience at Johnson & Johnson.

Medical-device engineer and former chief executive of Fisher & Paykel Healthcare.

Healthcare and consumer-technology executive with extensive international leadership experience at Philips.

Engineer with manufacturing and regional leadership experience at Cochlear; appointed CEO and president in January 2018.

Former chief executive of technology and media businesses, experienced in digital transformation and corporate governance.

Chris Wade co-founded Isomer Capital and is a Partner. He co-leads fund investing, leads company co-investments and manages Japanese limited-partner relationships and the corporate-investor programme. Previously he was a technology entrepreneur and a venture partner with Octopus Ventures and Entrepreneur First. UK legal filings identify Christopher John Wade. He is a different person from Patient Square Capital’s chief financial officer Chris Wade.

Joe Schorge founded and leads Isomer Capital as Managing Partner. He identified the opportunity to build diversified access to European technology venture capital in the early 2010s. His responsibilities include investing, portfolio management and development of the firm and team. Earlier experience spans technology operations and investing in the United States and Europe. The manager’s UK legal filings also identify him as R Joseph Schorge.

Dawn Dobras is a co-founder and general partner of Capital F and an operator with more than three decades of experience scaling brands. She previously led Credo Beauty and is an entrepreneur-in-residence at Harvard Business School, where she earned her MBA. She supports founders building in health, AI and digital commerce.

Margaret Coblentz is a co-founder and general partner of Capital F. She grew a major retailer’s ecommerce division and founded and bootstrapped luxury direct-to-consumer brand Frances Austen through an acquisition. She is a Stanford Graduate School of Business and UCLA alumna and a founding member of The Council Angels.

Biotechnology business builder with company management and commercialization experience.

Scientist and biotechnology entrepreneur; founded GeneProof in Brno.

Performance marketing entrepreneur; founded XLMedia and Team Odeon.

Technology entrepreneur and investor; founded cloud provider VSHosting.

Digital marketing entrepreneur and startup mentor; co-founded Feedyou.

Previously investment associate and investment manager at Lighthouse Ventures.

IT entrepreneur and investor; founded systems integrator Pontech.

Technology acquisition specialist; previously led corporate development at AVG.

Startup investor and mentor; founded the Prague Startup Centre.

Suryansh Chandra co-founded Automata with Mostafa ElSayed after working in computational design at Zaha Hadid Architects. Automata’s own CEO biography says he launched The Mind Distillery in2020 and remained an Automata director until2021. His historical founding affiliation is preserved; he is absent the current operating roster and no exact employment end date is guessed.

Current-status correction reviewed7October2026: Murali Venkatesan announced in his own public post that the preceding week was his final week at Danaher after seven and a half years. His Danaher Ventures leadership is therefore former, although the corporate page still labels him regional head and the January2026 Automata release used Global Head. Exact employment-end day and successor are undisclosed. This employment departure does not establish resignation from his separately recorded Automata statutory board appointment. His official Danaher biography describes electrical/computer engineering doctoral training at Illinois, earlier Lam Research and Illumina work, Stanford Executive Program and University of Western Australia degrees; the URL alone does not substantiate an MD degree. Previous sourced biography, subject to the current-status correction above: Murali Venkatesan is a Danaher Ventures executive leading healthcare and biotechnology investment and partnership work. Danaher’s current own biography calls him Vice President and Head of Danaher Ventures, Americas and Europe, with earlier technology roles at Illumina and Lam Research and an electrical and computer engineering PhD. Automata’s January2026 financing announcement confirms his board appointment; CompaniesHouse records the actual legal director appointment November6,2025 under Bala Murali K Venkatesan. No personal check is inferred.

Nan Li is a Dimension co-founder and managing partner working at the intersection of computing and life science. Biocom’s own professional biography specifically names Automata among his investments. CompaniesHouse confirms his Automata director appointment July31,2023. Distinct from unrelated academics and economists with the same name; no personal cash check inferred. Dimension’s current Investment directory and March2026 legal filing confirm Nan Li as co-founder/managing partner. His existing authentic portrait and separate current Automata statutory directorship are preserved.

Kamran Adle is an Automata director appointed January15,2024 according to CompaniesHouse. Octopus Ventures’ own profile identifies him as a health-investment partner with entrepreneurship and earlier JPMorgan experience. Institutional board representation does not establish a personal cash investment.

John D. Young is a former Pfizer executive who retired in 2022 and now advises Automata. Contributes pharmaceutical leadership, commercial strategy and scientific-development experience. His advisory role is distinct from a statutory director or personal investment.

Rui Campos is vice president of product at Automata. Product executive with experience developing and scaling products in automation and regulated industries.

Patrick Jamieson is senior vice president of operations at Automata. Operations executive with experience at Alloy Therapeutics, Ginkgo Bioworks and other technology and life-sciences businesses.

Michael Asham is global head of sales (current heading; biography says presales) at Automata. Molecular biologist and laboratory robotics specialist with experience in genomics, diagnostics and liquid handling. Own current heading says Global Head of Sales; the body retains an older Presales title.

Joe Stringer is executive chairman and president of corporate development at Automata. Healthcare executive and former Octopus investor responsible for corporate development and strategic relationships. His earlier investment activity was on behalf of institutions, not an inferred personal cash check.

Henni Roini is chief of staff at Automata. Oversees strategic projects, board reporting and company operations. Previously worked in venture investing at Balderton Capital and commercial roles at HubSpot.

Jennifer Howson is chief financial officer at Automata. Chartered accountant and finance executive with previous roles at Diageo, L’Oreal and PwC and experience building growing consumer businesses.

Mostafa ElSayed is ceo and co-founder at Automata. Architect and computational-design researcher who co-founded Automata with Suryansh Chandra after working at Zaha Hadid Architects. Leads its transition from affordable robotic arms to laboratory automation.

Wizdom Powell is a Hopelab board member and the inaugural CEO of Unified Youth. Her work spans mental and behavioral health, education, public policy and community interventions. She earned psychology and public-health graduate degrees at the University of Michigan and has held tenured academic appointments.

Tracey Kirui is Hopelab’s chief of staff and strategic partnerships, coordinating priorities with the CEO and building mission-related partnerships. Earlier work spans federal health policy, Medicaid and behavioral-health strategy and inclusive-leadership consulting. She also serves on the Lifelong Medical Care board.

Stefano Bertozzi chairs Hopelab’s board. His background includes health-policy scholarship at UC Berkeley, leading HIV and tuberculosis programs at the Gates Foundation, evaluation research at Mexico’s National Institute of Public Health and leadership of the WHO Global Programme on AIDS. Older institutional titles in the Hopelab biography are background affiliations rather than newly verified current outside appointments.

Samira Pingali is a principal leading translational science at Hopelab. She connects behavioral-science research with practical opportunities in adolescent development and well-being, including support for underrepresented researchers. She holds an MPH from Columbia University and has worked across mental-health research, operations and policy.

Sabrina Fisher directs finance at Hopelab. Her earlier nonprofit financial-leadership roles include the Campaign Legal Center, Brookings Economic Studies Program and the Society for Neuroscience. She holds a public-policy master’s degree from American University.

Robin Raskob is Hopelab’s senior manager for media and editorial. She oversees editorial work and media relations, creating content that represents young people’s experiences and supports mental-health equity.

Robin Hayashi is Hopelab’s creative lead, working in graphic design, design research and strategy. Earlier experience includes IDEO.org, IDEO and MIT. She holds a graphic-design BFA from the Rhode Island School of Design.

Phuong Pham is publicly listed as Hopelab’s director of communications and narrative change. Her experience combines digital media, storytelling and philanthropy, including earlier work at SoCal Grantmakers, Mission Investors Exchange and the Vilcek Foundation. The page biography retains an earlier marketing and digital-strategy title; the current directory title is used for her Hopelab role.

Pam Omidyar founded Hopelab, initially exploring whether a video game could improve treatment adherence among young people with cancer. That work led to the scientifically evaluated Re-Mission game. She remains a guiding figure at Hopelab and co-founded The Omidyar Group with Pierre Omidyar.

Nathaan Demers is a principal investor at Hopelab and a psychologist with clinical and leadership experience. His work connects behavioral health, technology and care systems. He earned his doctorate at the University of Denver and has worked in counseling, inpatient care and integrated primary care.

Monique Jaquez manages employee experience and office operations at Hopelab. Her earlier work included patient care and advocacy, and she has volunteered with community and grassroots organizations.

Mike Parent is a principal researcher at Hopelab, leading research partnerships and projects in youth mental health. He holds a doctorate in counseling psychology and an MBA and brings approximately fifteen years of research experience.

Melina Taylor directs information technology at Hopelab Foundation in San Francisco. Her experience covers cybersecurity, infrastructure, systems administration and IT strategy across education, biotech and other industries. She studied psychology at Yale.

Kim Bright is Hopelab’s vice president of finance and operations. She oversees organizational infrastructure and operational capabilities. Earlier finance, people and operations roles include the Campaign Legal Center, Brookings Metropolitan Policy Program and National Policing Institute, alongside technology-contract work at Booz Allen Hamilton.

Julie Tinker is a Hopelab principal focused on design, social impact and health equity. She develops programs centered on Black and Brown young people. Her training includes communication and sociology at Stanford and an MFA in design at the School of Visual Arts; the principal title is not an asserted investment role.

Juan Martinez is Hopelab’s vice president of strategic communications and policy. He leads communications and public-policy work focused on youth mental health. Earlier roles include communications leadership at the Legal Defense Fund, press secretary to Massachusetts Governor Deval Patrick and senior program officer at the Gates Foundation.

Joshua Lavra is a principal at Hopelab working across design, technology and youth mental health. Trained in chemical engineering, Lavra combines analytical methods with human-centered creative problem solving. The published principal role is not described as an investing position.

Jaspal Sandhu is Hopelab’s president and CEO. He leads its youth mental-health research, investments and funding programs, having previously served as executive vice president. His background combines design innovation, social entrepreneurship and health equity, including co-founding and leading Gobee.

Jana Haritatos is Hopelab’s chief science and innovation officer. She guides scientific priorities and partnerships and translates behavioral-science insights into youth-centered initiatives. She co-founded Purpose Commons with Tony Burrow.

Erin Sietstra heads investments at Hopelab, sourcing and managing companies addressing teen and young-adult mental health. She previously led transactions and business analytics at Johnson & Johnson Innovation and worked in healthcare strategy at Leerink Partners. She holds a Stanford MBA and a Harvard biology degree.

Emma Leiken directs youth power at Hopelab, focusing on technology policy and youth well-being. She previously led TikTok’s global youth-safety policy team and a youth-focused technology portfolio at Omidyar Network, where she co-founded the Responsible Technology Youth Power Fund.

Emma Bruehlman-Senecal is a principal researcher at Hopelab. She leads youth-engaged social and behavioral research and translates findings into design, research and policy recommendations. Earlier work included Hopelab’s Nod and imi products and postdoctoral research at UC Berkeley on mobile depression-treatment tools.

Elisa Sims is Hopelab’s accounting manager. She oversees accounting operations and brings experience across multiple industries to the organization’s financial management.

David Bayne directs policy at Hopelab, developing policy positions and engaging young people in policymaking. He previously led the Thurston County health department and held public-affairs and government-relations roles in Washington and Georgia public-health agencies. He earned an MPH at Emory University. He is distinct from IP Group executive David Baynes.

Courtney Chang is Hopelab’s head of strategy, aligning programs, partnerships and resources with its organizational priorities. She previously spent four years as Hopelab chief of staff and worked on health initiatives at IDEO.org and HIV/AIDS policy at PEPFAR. Her degrees include international health at Georgetown and an MBA/MPH at Johns Hopkins.

Brian Rodriguez leads people and culture at Hopelab. His role focuses on the organization’s workplace culture, employee experience and alignment with its mission and values.

Arielle Geismar is a Hopelab board member and a technology-policy organizer and strategist. Her work includes responsible technology, youth mental health, gender and LGBTQ+ advocacy. She formerly co-chaired Design It For Us and served as student body president at George Washington University.

Arianna Taboada directs learning and impact at Hopelab, overseeing equitable evaluation and organizational learning across investing, grants, research and field building. She trained in public-health social work at the University of North Carolina at Chapel Hill and previously worked on community-health research in Mexico and the United States.

Amy Green is a clinical psychologist and Hopelab’s head of research. She studies youth mental-health equity and implementation of evidence into policy and services. Her previous positions include UC San Diego academic appointments and vice president of research at The Trevor Project.

Alyssa Gabbidon is a research assistant at Hopelab working on youth-centered mental-health research, particularly for Black, Brown and Queer young people. She studied psychology and political science at Duke University and has experience in psychophysiology and policy research.

Aliza Lopez supports communications and policy at Hopelab. Her work covers youth participation, peer support and equitable access to mental-health resources. She previously worked on Headstream youth and accelerator programs and studied health, behavior and society at the University of Rochester.

Amy Hauck Newman, Ph.D., is NIDA scientific director and a senior investigator in the Molecular Targets and Medications Discovery Branch, Medicinal Chemistry Section. Her official NIH scientist biography describes designing and synthesizing ligands to study central nervous system G-protein coupled receptors and monoamine transporters, and developing tools for neuropharmacological research.

Lorenzo Leggio, M.D., Ph.D., is NIDA clinical director and a senior investigator in the Translational Addiction Medicine Branch. He founded the Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, a joint NIDA/NIAAA laboratory. His official NIH scientist biography describes translational addiction research, experimental medicine studies, clinical trials, biospecimen analysis and large-scale data analysis.

Daphne Zohar is the founder and former CEO and board director of PureTech Health, and the published founder, CEO and board member of Seaport Therapeutics. She co-founded PureTech’s Karuna Therapeutics and helped build its company-creation and research model. On April9,2024 she left PureTech’s CEO and director roles to lead Seaport, remaining a senior advisor and board observer under a dated agreement. PureTech’s2025 annual report confirms that she resigned the observer role August9,2025 and served as senior advisor through April8,2026. These historical PureTech appointments are not asserted to remain current. Her original Seaport portrait is authenticated by the named current leadership card; the site’s separate image filenames are not used to infer identity. No personal investment is inferred from founding or corporate ownership.

Published as Steffan Thorvaldsen; the official current Norwegian company register gives the full name Steffan Roxrud Thorvaldsen.

Davide Scaglia is listed by Friulia as Statutory Auditor. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Antonella Lonciari is listed by Friulia as Statutory Auditor. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Alberto Cappel is listed by Friulia as Chair, Board of Statutory Auditors. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Paolo Santin is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Luisa De Marco is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Renzo Chervatin is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; his genuine portrait and career biography are corroborated below by the published self-authored CV. His self-authored CV published by Fondazione Università Ca’ Foscari describes banking work from1985, roles at UniCredit from1998, and territorial-development responsibility for the northeast from2017. It lists regional ABI and other advisory affiliations. These are qualified CV career statements, distinct from his current Friulia board appointment; no separate employer role or personal investment is inferred.

Barbara Bortolussi is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Lucia Arena is listed in Friulia’s current public staff directory as Ufficio del Personale. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Massimiliano Viola is listed in Friulia’s current public staff directory as Sistemi Informativi. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Foschia is listed in Friulia’s current public staff directory as Amministrazione e Servizi Generali. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Sara Spogliarich is listed in Friulia’s current public staff directory as Segreteria Generale e Comunicazione. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Bertoz is listed in Friulia’s current public staff directory as Tesoreria & Debt Advisory. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandro Mazzi is listed in Friulia’s current public staff directory as Internal Audit e Compliance. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Gabrijel Zetko is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Elisa Tiberio is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Samuele Burlo is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Stefano Zonch is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.